AU2020324435B2 - Use of sepiapterin and metabolites thereof to treat radiation exposure - Google Patents

Use of sepiapterin and metabolites thereof to treat radiation exposure

Info

Publication number
AU2020324435B2
AU2020324435B2 AU2020324435A AU2020324435A AU2020324435B2 AU 2020324435 B2 AU2020324435 B2 AU 2020324435B2 AU 2020324435 A AU2020324435 A AU 2020324435A AU 2020324435 A AU2020324435 A AU 2020324435A AU 2020324435 B2 AU2020324435 B2 AU 2020324435B2
Authority
AU
Australia
Prior art keywords
mir
subject
radiation
administering
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020324435A
Other languages
English (en)
Other versions
AU2020324435A1 (en
Inventor
Eleonora MEZZAROMA
Ross MIKKELSEN
Christopher RABENDER
Neil Smith
Vasily YAKOVLEV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
PTC Therapeutics MP Inc
Original Assignee
Virginia Commonwealth University
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, PTC Therapeutics MP Inc filed Critical Virginia Commonwealth University
Publication of AU2020324435A1 publication Critical patent/AU2020324435A1/en
Application granted granted Critical
Publication of AU2020324435B2 publication Critical patent/AU2020324435B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2020324435A 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure Active AU2020324435B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
US62/882,937 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (2)

Publication Number Publication Date
AU2020324435A1 AU2020324435A1 (en) 2022-02-24
AU2020324435B2 true AU2020324435B2 (en) 2026-03-19

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020324435A Active AU2020324435B2 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN119837879A (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
KR20160068776A (ko) 2013-09-13 2016-06-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHENG-YI ZHANG et. al., "Tetrahydrobiopterin Protects against Radiation-induced Growth Inhibition in H9c2 Cardiomyocytes", CHIN MED J 2016 Vol. 129, pages 22, DOI: 10.4103/0366-6999.193455 *

Also Published As

Publication number Publication date
IL290321B1 (en) 2026-04-01
PT4009978T (pt) 2024-11-05
RS66096B1 (sr) 2024-11-29
CA3146477A1 (en) 2021-02-11
EP4009978B1 (en) 2024-09-25
EP4454712A2 (en) 2024-10-30
EP4454712A3 (en) 2025-01-01
SMT202500089T1 (it) 2025-03-12
IL290321A (en) 2022-04-01
CN119837879A (zh) 2025-04-18
MX2022001535A (es) 2022-03-04
PL4009978T3 (pl) 2025-02-24
JP2022543655A (ja) 2022-10-13
FI4009978T3 (fi) 2024-11-01
ES2994060T3 (en) 2025-01-16
AU2020324435A1 (en) 2022-02-24
DK4009978T3 (da) 2024-10-14
US20220273661A1 (en) 2022-09-01
WO2021026247A1 (en) 2021-02-11
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
JP2025098011A (ja) 2025-07-01
BR112022002029A2 (pt) 2022-06-07
HUE069012T2 (hu) 2025-02-28
SI4009978T1 (sl) 2025-03-31
CN114555090A (zh) 2022-05-27
EP4009978A1 (en) 2022-06-15
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
AU2020324435B2 (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
AU2024200693B2 (en) Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
Wang et al. The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest
US20090318534A1 (en) Methods and compositions for the treatment of skin diseases and disorders
JP2018507244A (ja) 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬
WO2022053019A1 (en) Methods for treating metastasis with cathepsin c inhibitors
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
WO2021262799A1 (en) Anti-viral compounds and methods of using same
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
CN111166756B (zh) 20（S）-人参皂苷-Rg3在逆转胶质瘤细胞对化疗药物的耐药性中的用途
JP7854389B2 (ja) Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
EP4545076A1 (en) Lat1 selective inhibitors for use in the treatment of adverse ventricular -remodelling and of heart failure
CN101432000B (zh) 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
WO2022195579A1 (en) Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害